Evogliptin
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Evogliptin: From Type 2 Diabetes Mellitus to Opsismodysplasia
One-Sentence Summary
Evogliptin is a DPP-4 inhibitor originally used to treat type 2 diabetes mellitus. The TxGNN model predicts it may be effective for Opsismodysplasia, a rare skeletal dysplasia. However, there are currently 0 clinical trials and 0 publications supporting this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 0.9935 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (3 of 3) – CDSCO approval status is not included in this data |
| Number of Listed Products | 3 (valid: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, evogliptin belongs to the DPP-4 inhibitor class. These drugs slow the breakdown of incretin hormones, which helps control blood sugar in type 2 diabetes.
Opsismodysplasia is a rare skeletal disorder caused by loss-of-function mutations in INPPL1 (SHIP2). These mutations affect PI3K/AKT signaling and bone formation (endochondral ossification). No established link connects DPP-4 inhibition to SHIP2 or to skeletal development pathways, so the mechanistic basis for this prediction is weak.
The very high TxGNN score (0.9935) should be read as a model-derived association only. No trials, literature, or preclinical data back it up. Other top-ranked predictions (thiamine-responsive dysfunction syndrome, focal stiff limb syndrome, classic stiff person syndrome, drug-induced localized lipodystrophy) share the same limitation. The stiff-person spectrum conditions have a speculative immune-modulation rationale through DPP-4/CD26 on T cells, but this is hypothesis-level only.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 233532 | Valera M 1000 Tablet SR | Strip of 15 sustained-release tablets | Not specified |
| 233304 | Valera Tablet | Strip of 15 tablets | Not specified |
| 233332 | Valera M 500 Tablet SR | Strip of 15 sustained-release tablets | Not specified |
All three authorizations are valid registrations held by Alkem Laboratories Ltd, in oral form.
Review correction (2026-11-06): Originally stated: “All three authorizations are valid single-ingredient registrations held by Alkem Laboratories Ltd, in oral form.” Removed: it described the products as single-ingredient or combination products in a way that did not match the Indian medicine data (the Indian Medicine Dataset as of 2026-11-06). Source: Indian Medicine Dataset.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the TxGNN model score, with no clinical trials or publications and no plausible mechanistic link between DPP-4 inhibition and opsismodysplasia. Evidence level is L5.
To proceed, the following is needed:
- Detailed mechanism of action data (MOA) for evogliptin
- Package insert safety information (warnings and contraindications) from the India regulatory source
- Preclinical or mechanistic studies exploring any connection between DPP-4 and INPPL1/SHIP2 or PI3K/AKT signaling in skeletal development
- Reassessment of other predicted indications, which have the same evidence gap
Review Log
Below is the review log for this page: statements checked against official Indian medicine data (the Indian Medicine Dataset used by this site). Corrections are limited to basic factual statements; model predictions, evidence levels, and conclusions were not rewritten.
| Review date | Item | Action | Source |
|---|---|---|---|
| 2026-11-06 | Removed: “single-ingredient” | Corrected | Indian Medicine Dataset |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.